PYC Therapeutics Limited

Equities

PYC

AU000000PYC7

Biotechnology & Medical Research

Market Closed - Australian S.E. Other stock markets 02:10:04 2024-05-21 am EDT			5-day change	1st Jan Change
0.105 ^AUD	+5.00%		+5.00%	-4.55%

May. 16	PYC Therapeutics Completes Dosing for Eye Disease Trial; Shares Fall 5%	MT
May. 09	Transcript : PYC Therapeutics Limited - Special Call

PYC Therapeutics Limited Appoints Michael Rosenblatt, MD, to Its Board of Directors

March 16, 2021 at 07:11 pm EDT

PYC Therapeutics announced the appointment of Michael Rosenblatt, MD, to its Board of Directors. Dr. Rosenblatt is a Senior Partner at Flagship Pioneering and the former Chief Medical Officer of Merck, one of the world's leading global biopharmaceutical companies. He currently serves on the Board of Directors of the Flagship companies Rubius Therapeutics, Cygnal Therapeutics and Ohana Biosciences.

Latest news about PYC Therapeutics Limited

PYC Therapeutics Completes Dosing for Eye Disease Trial; Shares Fall 5%	May. 16	MT
Transcript : PYC Therapeutics Limited - Special Call	May. 08
Australian Shares Rebound Amid Easing Middle East Tensions, Ahead of Local Inflation Data	Apr. 22	MT
PYC Therapeutics Confirms Safety, Tolerability of Kidney Medication in Animal Study	Apr. 21	MT
PYC Therapeutics Raises AU$13.5 Million via Retail Offer; AU$21.2 Million Retail Shortfall Placement Announced	Apr. 10	MT
PYC Therapeutics Raises AU$40 Million via Entitlement Offer	Mar. 17	MT
PYC Therapeutics to Raise Up to AU$75 Million for Advancing Drug Candidates	Mar. 14	MT
PYC Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 29	CI
PYC Therapeutics Receives AU$4.5 Million Upfront Fee for Drug Discovery Collaboration	Feb. 16	MT
Transcript : PYC Therapeutics Limited - Special Call	Feb. 01
PYC Therapeutics to Launch Google Cloud-Hosted Drug Discovery Project; Shares Fall 5%	Jan. 01	MT
Transcript : PYC Therapeutics Limited - Shareholder/Analyst Call	Nov. 23
Transcript : PYC Therapeutics Limited - Special Call	Nov. 16
Pyc Therapeutics Announces the Results of A Study Conducted in Human 3-Dimensional Models Derived from Patients with End-Stage Renal Failure Due to Autosomal Dominant Polycystic Kidney Disease	Nov. 13	CI
PYC Therapeutics Completes Dosing in Second Patient Cohort for Retinitis Pigmentosa Clinical Trial	Nov. 03	MT
PYC Reports Positive Results from Preclinical Studies of Rare Eye Disease Drug	23-10-05	MT
Transcript : PYC Therapeutics Limited - Special Call	23-10-04
PYC Therapeutics Advances to Second Dose Cohort of Phase 1 Trial Following Safety Clearance	23-09-22	MT
PYC Therapeutics Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-31	CI
PYC Therapeutics Limited Announces US FDA Designates PYC's Lead as a Fast Track Development Program	23-08-11	CI
PYC Therapeutics Raises Vision Pharma Shareholding to 96.2%	23-08-09	MT
PYC Therapeutics' RP11 Investigational Drug Candidate Secures Fast Track Designation from US FDA; Shares Climb 3%	23-08-01	MT
PYC Therapeutics Completes Toxicology Testing of Retinitis Pigmentosa Medication	23-07-18	MT
PYC Therapeutics Doses First Patient in Blinding Eye Disease Trial	23-06-29	MT
Pyc Appoints Andrew Taylor as Joint Company Secretary	23-06-01	CI

Chart PYC Therapeutics Limited

Duration

Period

More charts

Company Profile

PYC Therapeutics Limited is an Australia-based clinical-stage biotechnology company creating a new generation of ribonucleic acid (RNA) therapies to change the lives of patients with genetic diseases. The Company utilizes its proprietary drug delivery platform to enhance the potency of precision medicines within the rapidly growing and commercially proven RNA therapeutic class. Its drug development programs target monogenic diseases - the indications with the highest likelihood of success in clinical development. Its first-in-class drug programs include Retinitis Pigmentosa type 11, (VP-001), Polycystic Kidney Disease, (PYC-003), Autosomal Dominant Optic Atrophy (ADOA) (PYC-001) and Phelan-McDermid Syndrome (PMS) (PYC-002). The Company's VP-001 program is a lead asset for a blinding eye disease of childhood progressed through multiple patient cohorts in the ongoing single ascending dose clinical trial. ADOA is a progressive and blinding eye disease.

Sector

Biotechnology & Medical Research

Calendar

2024-08-26 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for PYC Therapeutics Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.1 AUD

Average target price

0.2933 AUD

Spread / Average Target

+193.33%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
PYC THERAPEUTICS LIMITED	-4.55%	312M
MODERNA, INC.	+41.79%	54.04B
IQVIA HOLDINGS INC.	-0.56%	41.92B
LONZA GROUP AG	+49.51%	41.96B
CELLTRION, INC.	-7.20%	28.35B
ICON PUBLIC LIMITED COMPANY	+12.59%	26.35B
ALNYLAM PHARMACEUTICALS, INC.	-21.51%	19B
BIO-TECHNE CORPORATION	+6.92%	13B
UNITED THERAPEUTICS CORPORATION	+24.91%	12.19B
MEDPACE HOLDINGS, INC.	+29.60%	12.28B

Other Biotechnology & Medical Research